| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S82790-1mg买3赠1 |
99.20% | ￥80.00 |
>10 | - | - | - | - |
|
S82790-5mg买3赠1 |
99.20% | ￥110.00 |
>10 | - | 2 | - | - |
|
S82790-10mg买3赠1 |
99.20% | ￥190.00 |
>10 | - | 2 | - | - |
|
S82790-25mg买3赠1 |
99.20% | ￥390.00 |
>10 | 2 | 2 | - | - |
|
S82790-50mg买3赠1 |
99.20% | ￥590.00 |
>10 | - | - | - | - |
|
S82790-100mg买3赠1 |
99.20% | ￥1020.00 |
>10 | - | - | - | - |
|
S82790-200mg买3赠1 |
99.20% | ￥1900.00 |
>10 | - | - | - | - |
|
| 产品描述： | Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | JAK1:0.043 μM (IC50);JAK2:0.2 μM (IC50);JAK3:2.3 μM (IC50);Tyk2:4.7 μM (IC50);JAK | ||||||||||||||||||||
| 体外研究： | In biochemical assays, Upadacitinib is 74-fold more selective for JAK-1 than for JAK-2 (which is involved in erythropoiesis) and 58-fold more selective for JAK-1 than for JAK-3 (which is involved in immunosurveillance). The enhanced selectivity of Upadacitinib for JAK-1 over JAK-2 and JAK-3 may offer an improved benefit–risk profile in patients with RA range | ||||||||||||||||||||
| 体内研究： | Upadacitinib (0.1-10 mg/kg; oral gavage; twice a day for 10 days) demonstrates efficacy in rat arthritis models. Animal Model: Female Lewis rats (Rat adjuvant-induced arthritis model) Dosage: 0.1, 0.3, 1, 3, 10 mg/kg Administration: Oral gavage; twice a day for 10 days Result: Inhibited disease pathology in rat adjuvant induced arthritis. | ||||||||||||||||||||
| 参考文献： | 1. Nakayamada S, et al. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs. 2016 Oct;30(5):407-419. 2. J. Voss, et al. THU0127 Pharmacodynamics of A Novel JAK1 Selective Inhibitor in Rat Arthritis and Anemia Models and in Healthy Human Subjects. doi 10.1136/annrheumdis-2014-eular.3823. 3. Parmentier JM, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018 Aug 28;2:23. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京